date:Feb 09, 2022
pplication. Ideally, this would also contain additional information to further strengthen the evidence.
The possible new application would be assessed again by the EFSA NDA panel, taking into account all the evidence that will be submitted and by weighing the evidence. The outcome of this assessment cannot be anticipated, states EFSA.
Beta-glucan has been the focus of increasing attention, with Lallemand Bio-Ingredients previously arguing it is on its way to becoming as much of a household na